Loading stock data…
LENZ
$8.88-0.10 (-1.11%)
Market ClosedLast close May 1
LENZ Therapeutics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
LENZ Therapeutics, Inc. in the Healthcare sector is trading at $8.88. The stock is currently near its 52-week low of $8.25, remaining 63.9% below its 200-day moving average. Technical signals show neutral RSI of 41 and bullish MACD crossover, explaining why LENZ maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 41) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$8.88
Potential Upside
5%
Whystock Fair Value$9.32
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus7 analysts
Mean target$39.57+345.6%
Range$20.00 – $60.00
Fundamentals
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of pre...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$313.23M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.29
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-18.43%
Volume
Today's trading volume
839,914
Recent News
President of LENZ Therapeutics Picks Up 57% More Stock
Potential LENZ Therapeutics, Inc. ( NASDAQ:LENZ ) shareholders may wish to note that the President, Evert...
The Consensus EPS Estimates For LENZ Therapeutics, Inc. (NASDAQ:LENZ) Just Fell Dramatically
Market forces rained on the parade of LENZ Therapeutics, Inc. ( NASDAQ:LENZ ) shareholders today, when the analysts...
Why Lenz Therapeutics Stock Plummeted by Almost 20% This Week
It failed to meet expectations for its final quarter of 2025.
LENZ Therapeutics, Inc. Q4 2025 Earnings Call Summary
Moby summary of LENZ Therapeutics, Inc.'s Q4 2025 earnings call
LENZ Therapeutics Inc (LENZ) Q4 2025 Earnings Call Highlights: Strong Cash Position and ...
LENZ Therapeutics Inc (LENZ) ends 2025 with robust financial health and a successful product launch, despite facing challenges in market adoption and increased operating expenses.